OROS Hydromorphone Development Unaffected By Palladone Withdrawal, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson says that the withdrawal of Purdue Pharma's Palladone (hydromorphone extended release) will not affect development of its OROS hydromorphone opioid analgesic